Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hidradenitis Suppurativa | 4 | 2020 | 9 | 2.710 |
Why?
|
| Methotrexate | 2 | 2020 | 64 | 1.370 |
Why?
|
| Dermatologic Agents | 2 | 2020 | 229 | 1.050 |
Why?
|
| Skin Neoplasms | 7 | 2007 | 214 | 0.860 |
Why?
|
| Lichen Planus | 2 | 2020 | 10 | 0.850 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 881 | 0.850 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 9 | 0.720 |
Why?
|
| Vulvar Diseases | 1 | 2020 | 4 | 0.710 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 99 | 0.700 |
Why?
|
| Fibromyalgia | 1 | 2020 | 25 | 0.680 |
Why?
|
| Crohn Disease | 1 | 2019 | 26 | 0.680 |
Why?
|
| Quality of Life | 2 | 2019 | 946 | 0.650 |
Why?
|
| Pemphigoid Gestationis | 1 | 2018 | 3 | 0.630 |
Why?
|
| Pruritus Vulvae | 1 | 2018 | 1 | 0.630 |
Why?
|
| Vulvitis | 1 | 2018 | 1 | 0.630 |
Why?
|
| Adult | 12 | 2020 | 9375 | 0.490 |
Why?
|
| Female | 20 | 2020 | 19999 | 0.490 |
Why?
|
| Humans | 28 | 2020 | 32082 | 0.480 |
Why?
|
| Opportunistic Infections | 2 | 2002 | 17 | 0.430 |
Why?
|
| Melanosis | 1 | 2009 | 15 | 0.330 |
Why?
|
| Dermis | 3 | 2002 | 16 | 0.320 |
Why?
|
| Dermatitis, Atopic | 2 | 2018 | 102 | 0.320 |
Why?
|
| Cryoglobulinemia | 1 | 2008 | 5 | 0.310 |
Why?
|
| Skin Ulcer | 1 | 2008 | 11 | 0.310 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3505 | 0.310 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2008 | 12 | 0.300 |
Why?
|
| Cellulitis | 1 | 2007 | 10 | 0.290 |
Why?
|
| Eosinophilia | 1 | 2007 | 11 | 0.290 |
Why?
|
| Transients and Migrants | 1 | 2009 | 297 | 0.250 |
Why?
|
| Middle Aged | 10 | 2020 | 11834 | 0.250 |
Why?
|
| Diagnosis, Differential | 6 | 2008 | 516 | 0.250 |
Why?
|
| Neurodermatitis | 2 | 2018 | 3 | 0.240 |
Why?
|
| Male | 10 | 2020 | 19202 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 288 | 0.230 |
Why?
|
| Actinomycetales | 1 | 2002 | 2 | 0.220 |
Why?
|
| Lip Neoplasms | 1 | 2002 | 2 | 0.220 |
Why?
|
| Syphilis, Cutaneous | 1 | 2002 | 2 | 0.220 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2002 | 2 | 0.220 |
Why?
|
| Leukemia, Lymphoid | 1 | 2002 | 3 | 0.220 |
Why?
|
| Fusarium | 1 | 2002 | 2 | 0.220 |
Why?
|
| Corynebacterium Infections | 1 | 2002 | 3 | 0.220 |
Why?
|
| Fibrosarcoma | 1 | 2002 | 4 | 0.220 |
Why?
|
| Lymphangioma | 1 | 2002 | 7 | 0.220 |
Why?
|
| Dermatomycoses | 1 | 2002 | 7 | 0.220 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2002 | 6 | 0.210 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2002 | 4 | 0.210 |
Why?
|
| Angiomatosis | 1 | 2002 | 4 | 0.210 |
Why?
|
| Nevus, Pigmented | 1 | 2002 | 6 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2002 | 8 | 0.210 |
Why?
|
| Granuloma | 1 | 2002 | 14 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2002 | 12 | 0.210 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2002 | 13 | 0.210 |
Why?
|
| Scalp | 1 | 2002 | 38 | 0.210 |
Why?
|
| Adenoma | 1 | 2002 | 35 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 44 | 0.210 |
Why?
|
| Prevalence | 2 | 2020 | 989 | 0.210 |
Why?
|
| Hispanic Americans | 1 | 2009 | 940 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 130 | 0.190 |
Why?
|
| Skin Diseases | 1 | 2002 | 142 | 0.180 |
Why?
|
| Genitalia | 1 | 2020 | 8 | 0.180 |
Why?
|
| Aged | 6 | 2020 | 10308 | 0.180 |
Why?
|
| Melanoma | 3 | 2007 | 164 | 0.170 |
Why?
|
| Observer Variation | 1 | 2019 | 105 | 0.160 |
Why?
|
| Health Surveys | 1 | 2019 | 198 | 0.160 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2018 | 1 | 0.160 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 7 | 0.160 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 11 | 0.160 |
Why?
|
| Photochemotherapy | 1 | 2018 | 21 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 3990 | 0.150 |
Why?
|
| Young Adult | 2 | 2018 | 2665 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2019 | 895 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 765 | 0.140 |
Why?
|
| Postmenopause | 1 | 2018 | 430 | 0.130 |
Why?
|
| Pregnancy | 1 | 2018 | 996 | 0.120 |
Why?
|
| Neurilemmoma | 2 | 2005 | 16 | 0.120 |
Why?
|
| Skin | 2 | 2008 | 211 | 0.110 |
Why?
|
| Immunocompromised Host | 2 | 2002 | 51 | 0.100 |
Why?
|
| Psoriasis | 1 | 2018 | 360 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3304 | 0.100 |
Why?
|
| Adolescent | 4 | 2009 | 3568 | 0.100 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 159 | 0.080 |
Why?
|
| Amyloidosis | 1 | 2008 | 14 | 0.080 |
Why?
|
| Age Distribution | 1 | 2009 | 206 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 462 | 0.070 |
Why?
|
| Cetirizine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Anti-Allergic Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Blister | 1 | 2007 | 7 | 0.070 |
Why?
|
| Prednisone | 1 | 2007 | 61 | 0.070 |
Why?
|
| Pruritus | 1 | 2007 | 47 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2007 | 187 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 70 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 263 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 770 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2007 | 107 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 35 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 39 | 0.060 |
Why?
|
| Leiomyoma | 1 | 2004 | 16 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 27 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 190 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1542 | 0.060 |
Why?
|
| North Carolina | 1 | 2009 | 1538 | 0.060 |
Why?
|
| Infant | 2 | 2008 | 1061 | 0.060 |
Why?
|
| Parakeratosis | 1 | 2003 | 3 | 0.060 |
Why?
|
| Axilla | 1 | 2003 | 18 | 0.060 |
Why?
|
| Leprosy | 1 | 2002 | 2 | 0.050 |
Why?
|
| Neurofibroma | 1 | 2002 | 2 | 0.050 |
Why?
|
| Nevus, Blue | 1 | 2002 | 3 | 0.050 |
Why?
|
| Leishmaniasis | 1 | 2002 | 3 | 0.050 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2002 | 5 | 0.050 |
Why?
|
| Germinal Center | 1 | 2002 | 5 | 0.050 |
Why?
|
| Giant Cells | 1 | 2002 | 4 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2002 | 5 | 0.050 |
Why?
|
| Clone Cells | 1 | 2002 | 36 | 0.050 |
Why?
|
| Salivary Glands, Minor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Sarcoidosis | 1 | 2002 | 28 | 0.050 |
Why?
|
| Mycoses | 1 | 2002 | 20 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 604 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 45 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2002 | 57 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2002 | 57 | 0.050 |
Why?
|
| Breast | 1 | 2002 | 68 | 0.050 |
Why?
|
| Cholesterol | 1 | 2002 | 252 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 534 | 0.030 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mast Cells | 1 | 2008 | 12 | 0.020 |
Why?
|
| Fluocinonide | 1 | 2008 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 15 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2008 | 9 | 0.020 |
Why?
|
| Epidermis | 1 | 2008 | 30 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2008 | 37 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 145 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2007 | 17 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2007 | 48 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 89 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 166 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 317 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 447 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Mitosis | 1 | 2005 | 25 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 581 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2005 | 31 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2005 | 185 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2005 | 288 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 876 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 483 | 0.010 |
Why?
|
| Triamcinolone | 1 | 2003 | 11 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 353 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 725 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 469 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2003 | 139 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 943 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 407 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 1496 | 0.010 |
Why?
|
| Child | 1 | 2007 | 2439 | 0.010 |
Why?
|